Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review

Authors Suzanne A Ligthart, Eric P Moll van Charante, Willem A Van Gool, et al

Published Date August 2010 Volume 2010:6 Pages 775—785

DOI http://dx.doi.org/10.2147/VHRM.S7343

Published 17 August 2010

Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, ­hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Dengue: factors driving the emerging epidemic

Ali M

Clinical Epidemiology 2013, 5:461-463

Published Date: 19 November 2013

Superficial venous thrombosis: disease progression and evolving treatment approaches

Litzendorf ME, Satiani B

Vascular Health and Risk Management 2011, 7:569-575

Published Date: 31 August 2011

Optimal management of familial hypercholesterolemia: treatment and management strategies

Mohammad Hassan Nemati, Behrooz Astaneh

Vascular Health and Risk Management 2010, 6:1079-1088

Published Date: 3 December 2010

Small coronary vessel angioplasty: outcomes and technical considerations

Sudhir Rathore

Vascular Health and Risk Management 2010, 6:915-922

Published Date: 11 October 2010

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Vascular Health and Risk Management 2010, 6:855-867

Published Date: 29 September 2010

Effectiveness of percutaneous laser revascularization therapy for refractory angina

Michael McGillion, Allison Cook, J Charles Victor, et al

Vascular Health and Risk Management 2010, 6:735-747

Published Date: 26 August 2010

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection

Domenico Galzerano, Cristina Capogrosso, Sara Di Michele, et al

Vascular Health and Risk Management 2010, 6:479-494

Published Date: 22 June 2010

Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy

Kittipan Rerkasem, Patrick J Gallagher, Robert F Grimble, Philip C Calder, Clifford P Shearman

Vascular Health and Risk Management 2008, 4:1259-1264

Published Date: 12 September 2008

Potential bias in ophthalmic pharmaceutical clinical trials

Paul Varner

Clinical Ophthalmology 2008, 2:401-411

Published Date: 30 June 2008

The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure

Ovidio De Freitas, Oliver Lenz, Alessia Fornoni, Barry J Materson

Vascular Health and Risk Management 2006, 2:139-144

Published Date: 25 January 2006